SLGL Stock Overview
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SLGL from our risk checks.
My Notes
NewNotes are coming soon
Sol-Gel Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.17 |
| 52 Week High | US$8.08 |
| 52 Week Low | US$3.94 |
| Beta | 1.28 |
| 1 Month Change | 20.79% |
| 3 Month Change | 8.61% |
| 1 Year Change | -30.97% |
| 3 Year Change | -52.48% |
| 5 Year Change | -51.23% |
| Change since IPO | -62.10% |
Recent News & Updates
Recent updates
Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M
Aug 04These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat
May 17
We Think That There Are Issues Underlying Sol-Gel Technologies' (NASDAQ:SLGL) Earnings
Apr 15Downgrade: Here's How Analysts See Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Performing In The Near Term
Apr 05We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth
Nov 23We Think Sol-Gel Technologies (NASDAQ:SLGL) Needs To Drive Business Growth Carefully
Aug 04Here's Why Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) CEO May Deserve A Raise
Jul 01Sol-Gel says no FDA notification regarding its marketing application for EPSOLAY
Apr 27Newsflash: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analysts Have Been Trimming Their Revenue Forecasts
Mar 05We're Not Very Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate
Feb 02What Type Of Returns Would Sol-Gel Technologies'(NASDAQ:SLGL) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 29
FDA accepts Sol-Gel application for Twyneo
Dec 07Sol-Gel: Slow And Steady Topical Technology
Nov 19These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat
Nov 18Sol-Gel Technologies EPS beats by $0.09, beats on revenue
Nov 12Shareholder Returns
| SLGL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.2% | -0.5% | 1.7% |
| 1Y | -31.0% | 4.6% | -9.6% |
Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: SLGL underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| SLGL volatility | |
|---|---|
| SLGL Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SLGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SLGL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 53 | Alon Seri-Levy | https://www.sol-gel.com |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products.
Sol-Gel Technologies Ltd. Fundamentals Summary
| SLGL fundamental statistics | |
|---|---|
| Market Cap | US$119.58m |
| Earnings (TTM) | US$4.89m |
| Revenue (TTM) | US$24.59m |
24.4x
P/E Ratio4.9x
P/S RatioIs SLGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGL income statement (TTM) | |
|---|---|
| Revenue | US$24.59m |
| Cost of Revenue | US$13.46m |
| Gross Profit | US$11.13m |
| Other Expenses | US$6.24m |
| Earnings | US$4.89m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 45.27% |
| Net Profit Margin | 19.90% |
| Debt/Equity Ratio | 0% |
How did SLGL perform over the long term?
See historical performance and comparison